Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes by Yeghiazaryan, Kristina et al.
Vasospastic individuals demonstrate significant similarity to
glaucoma patients as revealed by gene expression profiling in
circulating leukocytes
Kristina Yeghiazaryan,1 Josef Flammer,2 Selim Orgül,2 Kerstin Wunderlich,2 Olga Golubnitschaja1
1Department of Radiology, University of Bonn, Germany; 2University Eye Clinic, Basel, Switzerland
Purpose: There is growing evidence that vasospatic individuals could be predisposed to develop glaucoma. Vasospastic
deregulation is ensuing in activation of circulating leukocytes. In previous studies using “gene-hunting” strategies, we
demonstrated stable alterations in gene expression profiles of circulating leukocytes isolated from glaucoma patients with
vascular deregulation when compared to healthy individuals with no history of glaucomatous damage. The goal of this
study was to look for possible similarities in gene expression profiles of circulating leukocytes in vasospastic individuals
and glaucoma patients.
Methods: Normal-tension (NTG) and high-tension (HTG) glaucoma patients as well as individuals with vascular
deregulation (VD) and healthy controls were recruited for the gene expression analysis. The methodology of comparative
Expression Array analysis followed by highly sensitive quantitative real-time PCR has been used.
Results: Compared to the control group the expression of 146, 68, and 60 genes was found to be altered in NTG, HTG,
and VD groups respectively. Thirty-four genes demonstrated similar expressional alterations in NTG, HTG, and VD
groups versus controls, and only 21 genes demonstrated similar expressional alterations in NTG and HTG groups, having
no overlap with the VD group.
Conclusions: This result indicates a potential predisposition of vasospastic individuals to glaucomatous optic nerve
atrophy. The targeted expression profiles might be further considered for early/predictive glaucoma diagnosis.
Glaucomatous optic neuropathy (GON) is characterized
by a combination of retinal ganglion cell loss, activation of
astrocytes,  and  remodeling  of  the  lamina  cribrosa.  The
etiology of glaucoma and risk factors are only partially known
[1,2]. Although elevated intraocular pressure (IOP) has been
shown to be the major risk factor, there is a cohort of patients,
sometimes even at younger ages with normal IOP, developing
normal-tension glaucoma (NTG). A wealth of literature points
to the potential importance of hemodynamics in NTG, but
randomized  controlled  trials  are  not  yet  available  [3].  A
valuable diagnostic tool for ascertaining vasospastic diathesis
is the nailfold capillary microscopy. The best known blood-
born factor is an increased plasma level of endothelin-1 to
estimate  vasospastic  diathesis  [4].  Vasospasm,  frequently
observed in the young female subpopulation can potentially
predispose to several disorders, including glaucomatous optic
nerve head atrophy. Ocular ischemia resulting from blood
flow  deficits  may  play  a  major  role  in  the  initiation  of
glaucoma.  Indeed,  hypoxia  followed  by  high  secretion  of
excitatory amino acids and elevated levels of intracellular
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calcium may eventually lead to retinal ganglion cells death
[3,5,6].  The  molecular  pathways  involved  in  vasospastic
deregulation, which can potentially impact the GON, have not
yet  been  investigated.  In  our  previous  studies,  we
demonstrated  stable  alterations  in  gene  expression  of
circulating  leukocytes  isolated  from  glaucoma  patients
compared to controls [7–10]. The goals of this study were
- identification of possible similarities as well as
dissimilarities in gene expression profiles of circulating
leukocytes  between  vasospastic  individuals  and
glaucoma patients;
- identification of specific gene transcription patterns
in circulating leukocytes of glaucoma patients;
- selection of potential molecular targets in blood for
noninvasive  early  diagnostics  of  different  glaucoma
forms.
METHODS
Recruitment of patients and controls: Altogether 79 patients
and controls were recruited at the University Eye Clinic in
Basel. Patients and controls were well matched together from
viewpoint of age and gender. Blood samples (20 ml) were
collected  from  42  non-glaucomatous  non-vasospastic
individuals  (controls,  group  1),  six  non-glaucomatous
vasospastic individuals (VD), ten normal-tension glaucoma
(NTG)  individuals,  ten  high-tension  glaucoma  (HTG)
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2339individuals,  and  11  pseudoexfoliation  glaucoma  (PEX)
individuals.  All  glaucoma  patients  had  bilateral  typical
glaucomatous  optic  nerve  head  cupping  and  visual  field
defects with a mean deviation greater than 7 dB in the Octopus
program G1. For NTG patients, IOP never exceeded 21 mm
Hg, as assessed in at least two diurnal tension curves. The
diagnosis  of  vasospasm  was  based  on  nailfold
capillaromicroscopy findings. After local cooling of a finger,
all vasospastic individuals exhibited a stop in blood flow for
more than 20 s. Controls had an unremarkable ophthalmologic
examination and did not show any vasospastic response. No
patient or control subject had received either systemic or local
ocular  therapy  at  least  4  weeks  before  the  study.  All
investigations conformed with the principles outlined in the
Declaration of Helsinki and were performed with permission
from  the  Ethic’s  Committee  of  the  Medical  Faculty,
University  of  Basel,  Switzerland  (ClinicalTrials.govID:
NCT00327509). All recruited persons were informed about
the study and consented the data use.
Isolation  of  mononuclear  blood  cells:  Individual  blood
samples (20 ml) anti-coagulated with heparin were collected
from patients and controls. Leukocytes were separated using
Ficoll-Histopaque  gradients  (Histopaque  1077;  Sigma
Aldrich, St. Louis, MO) as described previously [9]. After
washing procedure (three times) with physiological buffer
solution (PBS, Biochrom AG, Berlin, Germany) cells were
pelleted and immediately frozen on dry ice and stored at -80
°C till molecular biological analysis.
synthesized  cDNA  was  stored  at  -20  °C  till  molecular
biological analysis.
Hybridization to Atlas HumanTM Cardiovascular Array:
Preparation of biotin-labeled cDNA probes—cDNA
(100 ng) was labeled using a SpotLightTM Random Primer
Labeling  kit  (Clontech,  Mountain  View,  CA).  Template
cDNA together with 5 µl of 10× Random Primer mix were
heated to 97 °C for 3 min in a final volume of 31 µl and chilled
quickly  on  ice.  After  adding  the  reaction  mix  (5  µl  10×
Klenow reaction buffer, 5 µl 10× Klenow labeling mix, 1 µl
Klenow  enzyme,  and  8  µl  sterile  water  [Clontech]),  the
labeling reaction was performed at 37 °C for 30 min. The
reaction was then stopped by adding 2 µl of 0.5 M EDTA
(pH 8.0).
Purification of biotin-labeled probe—Unincorporated
biotin-labeled  nucleotides  and  small  (<0.1  kb)  cDNA
fragments  were  removed  using  the  NucleoSpin  extraction
columns  (Clontech).  The  labeled  probe  was  mixed  with
binding  buffer  and  loaded  directly  on  spin  column.  After
centrifugation the column was washed three times and dried
briefly. Elution buffer was loaded onto the filter. Biotinylated
probe  was  collected  after  brief  centrifugation.  The
concentration of the newly synthesized biotin-labeled probes
was  determined  by  UV  spectroscopy.  Finally,  the  biotin-
labeled probes were stored at –20 °C until hybridization to the
Atlas™ Array (Clontech).
Hybridization       of       biotin-labeled       probes       to 
Atlas      Array  —   For      the  hybridization,
  Human     Cardiovascular    Array   (Clontech)    and
SpotLightTM Chemiluminescent Hybridization and Detection
kit (Clontech) were used. Each Atlas array (membrane) was
wetted by placing it in a dish of de-ionized H2O, after which
it  was  transferred  to  the  hybridization  bottle  and  pre-
hybridized in the hybridization mix at 42 °C for 3 h before the
hybridization.  Each  hybridization  reaction  was  performed
overnight at 42 °C with individual biotinylated cDNA probes.
These probes were denatured in 100 mM NaOH at 68 °C for
20 min and neutralized with 0.5 M NaH2PO4 (pH 7.0) at 68 °C
for  10  min  before  the  overnight  hybridization  in  the
Hybridizer (Techne Inc., Burlington, NJ).
Stringency  washes—The  hybridization  solution  was
discarded  and  the  membranes  were  washed  four  times  in
200 ml of wash solution 1 (2× saline-sodium citrate [SSC]
buffer and sodium dodecyl sulfate [SDS]) for 30 min at 60 °C
with continuous agitation. Wash solution 1 was then replaced
with wash solution 2 (0.1× SSC and 0.5% SDS), and the
membranes were washed two more times for 30 min at 48 °C.
Probe  detection  and  signal  visualization—The
membranes were incubated first in 25 ml blocking buffer per
Atlas array at room temperature for 1 h before the incubation
with  streptavidin-horse-radish  peroxidase  conjugate  (final
dilution  of  1:300)  for  1  h  with  constant  gentle  agitation.
Afterwards the membranes were washed four times in 1×
wash buffer (SpotLightTM Chemiluminescent Hybridization
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Isolation  of  total  RNA,  mRNA,  and  first-strand  cDNA
synthesis: Isolation of total RNA from aliquoted samples of
mononuclear blood cells were performed using Total RNA
Isolation Reagent (Thermo Fisher Scientific, ABgene product
line, Epsom, UK). After storing for 5 min on ice, 0.2 ml
chloroform per 1 ml RNA reagent was added. The samples
were vortexed and placed on ice for 5 min. The homogenate
was centrifuged at 12,000× g (4 °C) for 15 min. RNA samples
were transferred into new tubes. Equal volume of isopropanol
was added. Samples were stored overnight at -80 °C. After a
30 min centrifugation at 12,000× g (4 °C) total RNA was
sedimented.  RNA  samples  were  washed  twice  with  70%
ethanol and briefly dried. Total RNA Pellets were dissolved
in  diethylpyrocarbonate  (DEPC)-water.  The  isolation  of
mRNA was performed with an Oligotex mRNA Mini Kit
(Qiagen,  Hilden,  Germany).  Total  RNA  was  mixed  with
Oligotex Suspension consisting of polystyrene-latex particles
linkaged with dC10T30 oligonucleotides. mRNA samples were
hybridized  to  Oligotex.  mRNA-Oligotex  complexes  were
loaded on spin column, washed three times. mRNA were
eluted from column with sterile water. cDNA synthesis was
performed using the iScriptTM cDNA Synthesis Kit (Bio-Rad,
Hercules, CA). The reaction mix (mRNA Template, 5× iScript
reaction mix and iScript reverse transcriptase) was incubate
for 5 min at 25 °C, 30 min at 42 °C and 5 min at 85 °C. The
AtlasTMand Detection kit; Clontech) for 10 min with concomitant
equilibration in substrate equilibration buffer for 5 min at
room  temperature  before  the  incubation  in  8  ml  working
Reverse transcriptase PCR and real-time quantitative PCR :
In  order  to  detect  the  expression  of  the  target  genes  in
leukocytes and to optimize the reaction conditions for real-
time quantitative PCR, reverse transcriptase PCR (RT-PCR)
was performed using specific primer sets (Table 1). cDNA
synthesis was performed using the iScriptTM cDNA Synthesis
kit (Bio-Rad). The PCR mixture contained 1× PCR buffer
(16.6 mM ammonium sulfate, 67 mM Tris, pH 8.8, 6.7 mM
MgCl2,  10  mM  2-mercaptoethanol),  dNTPs  (each  at
1.25 mM), primer pairs (100 pM each per reaction), and 10 ng
of cDNA template in a final volume of 50 µl. Reactions were
hot-started at 95 °C for 5 min before adding 1.5 units of Taq
polymerase (Red-Hot®, Thermo Fisher Scientific, ABgene
product line) at the annealing temperature of 56 °C, followed
by polymerization at 72 °C for 1 min. Amplification was
carried out in DNA Thermal Cycler TC480 (Perkin Elmer,
Waltham, MA) for 45 cycles (denaturation for 45 s at 95 °C,
annealing for 45 s at 56 °C, and polymerization at 72 °C for
30 s), followed by a final 7-min extension at 72 °C. Negative
controls without DNA as well as positive controls with a
sequenced  template  were  performed  for  each  set  of  PCR
experiments. PCR products (50 µl) were directly loaded onto
3% agarose gels (wide range-agarose gels for analysis of DNA
fragments longer than 50 bp; Sigma), stained with ethidium
bromide after electrophoresis, directly visualized under UV
illumination, and imaged using a specialized imaging system
(Eurofins  MWG  Operon,  Ebersberg,  Germany).  The
specificity of each PCR amplification was controlled using
the site-specific restriction analysis of target PCR products.
The amplification products underwent an extraction from the
agarose gel, using a DNA isolation kit (DNA Gel Extraction
Kit;  Fermentas,  Vilnius,  Lithuania)  before  digestion.  The
products were digested in a final volume of 50 µl with 20 units
of  each  restriction  endonuclease  (see  Table  1)  for  2  h,
according  to  conditions  specified  by  the  manufacturer
(Fermentas), and imaged after electrophoresis.
In order to profile precisely the changes in an expression
of  target  genes,  real-time  quantitative  PCR  was  used.
SYBR® Green I (Invitrogen, Molecular Probes®, Carlsbad,
CA) was used as the intercalation dye and fluorescent reporter
molecule detecting the accumulation of the amplified double-
stranded product in the iCycler iQIM Detection System (Bio-
Rad). The synthesized cDNAs (50 ng; see RT-PCR) were used
for each real-time PCR analysis. The reaction mixtures had
the same contents as for RT-PCR with the exception of Red-
Hot® polymerase (Thermo Fisher Scientific, ABgene product
line),  which  was  substituted  for  Thermoprime  Plus  DNA
polymerase (Thermo Fisher Scientific, ABgene product line)
in  order  to  avoid  color  signal  disturbances.  The  same
amplification program was used in both qualitative RT-PCR
and quantitative real-time PCR analysis. The algorithm of the
iCycler iQIM detection system normalizes the reporter signal
(non-intercalated SYBR® Green I) to a passive reference and
multiplies  the  standard  deviation  (SD)  of  the  background
signal in the first few cycles by a default factor of 10 to
determine a threshold. The cycle at which this baseline level
is exceeded is defined as the threshold cycle (Ct). Ct depends
on the initial template copy number and is proportional to the
log of the starting amount of nucleic acid [11]. The data are
normalized by subtracting the difference of the Ct values of a
target gene from those of the housekeeping one (β-actin). The
relative expression levels were calculated for each sample
based on the differences in Ct values [11].
Statistical evaluation: Statistical significance was calculated
by the two-sided unpaired Student t test and was considered
significant at the p<0.05 level.
RESULTS
Expression array: The image of hybridized Atlas™ Human
Cardiovascular  Array  is  represented  in  Figure  1.  The
similarities as well as alterations in gene expression among
NTG, HTG, and VD groups versus controls are summarized
in Table 2.
Compared to the control group, the expression of 146, 68,
and 60 genes was found to be altered in NTG, HTG, and VD
groups, respectively; the same 53 genes were differentially
expressed in both NTG and HTG groups versus controls.
Among 146 genes differentially expressed specifically in the
TABLE 1. PRIMER SETS AND CORRESPONDING LENGTHS OF THE EXPECTED PCR PRODUCTS.
Genes Forward Primer Reverse Primer
Product
size, bp
Endonucleases for
product digestion
β-Actin TAAGGAGAAGCTGTGCTACG TGAAGGTAGTTTCGTGGATG 203 GsuI, LguI (SapI)
P2Y TCATCTCTCTGCTGGCTATC CTTGGTGCGTAGCTTCTG 347 RsaI, XbaI
ICAM1 AGTCACCTATGGCAACGAC GCCTCACACTTCACTGTCA 216 AluI, PstI
Na+/Ca2+ EP1 ACCACCAAGACAACTGTGAG CACGCAAATGCTTAATCTTC 244 CfrI (EaeI), PstI
MT1-MMP ATCTGTGACGGGAACTTTGA CTTCCTCTCGTAGGCAGTG 174 HhaI, HphI
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solution (the mix of luminol/enhancer solution and stable
peroxide solution) per membrane for 5 min. After removing
excess  liquid,  the  Atlas  arrays  were  processed  for
autoradiography  with  exposure  times  of  1,  2,  5,  10,  and
30 min. The exposed spots were further scanned and analyzed
with AtlasImage™ 2.0 software (Clontech).NTG group, we monitored 48 and 53 genes that were similarly
expressed  either  in  VD  or  in  HTG  groups,  respectively.
Among 68 genes differentially expressed specifically in the
HTG group, we found 43 genes to be similarly expressed in
the VD group only. The highest difference—146 genes—was
found to be between the NTG and control groups. In contrast,
the lowest difference—21 genes—was demonstrated to be
between VD and the overlap of NTG/HTG.
Thirty-four  genes  demonstrated  similar  expressional
alterations in NTG, HTG, and VD groups versus controls, as
presented in Table 3. As the differentially expressed overlap
VD/NTG/HTG was compared with the control group, the
following most significant differences were monitored:
Figure 1. Expression Array image. The
image of 588 genes (see AtlasTM Human
Cardiovascular  Array  in  Methods)  is
shown  specifically  for  the  group  of
individuals with vascular deregulation.
The  double  spots  marked  with  black
frames  show  the  most  stable
expressional  difference  in  vascular
deregulation  (VD),  normal-tension
(NTG)  and  high-tension  (HTG)
glaucoma  patients  groups  versus
controls.  These  double-spots  are
zoomed for the groups tested (ZOOM),
and the names of corresponding genes
as well as their positions in Atlas are
given.
TABLE 2. NUMBERS OF GENES AN EXPRESSION OF WHICH IS EITHER DIFFERENTIAL OR EQUAL AMONG THE GROUPS TESTED AS SHOWN BY “EXPRESSION ARRAY”.
Differential to control VD equal to VD Differential to
NTG→146 Control →528 NTG→109
HTG →68 NTG→48 K→60
VD→60 HTG→43 HTG→43
NTG = HTG→53 NTG = HTG →34 NTG = HTG→21
Thereby, 108 genes were found to be differentially expressed between NTG and HTG groups. 34 genes demonstrated similar
alteration for vasospastic individuals (VD) and both glaucoma-patient groups when compared to the healthy controls (see these
genes listed in Table 3).
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- Na+/Ca2+ exchange protein 1 (Na+/Ca2+ EP1)
- intercellular adhesion molecule 1 (ICAM1)
- cluster of tissue-remodeling metalloproteinases.
The  corresponding  images  for  the  groups  tested  are
shown in Figure 1.
Real-time PCR: The most stable, i.e., statistically significant
alterations in target transcripts for glaucoma patients versus
controls are shown in Figure 2.
P2Y expression values (encrypted gene 1)—The most
significant alteration in the transcription regulation of this
gene for glaucoma patients has been demonstrated. If any,
only traces of this transcript were detected in the control blood
samples. In contrast, significantly increased expression rates
were demonstrated for glaucoma patients.
ICAM1 expression values (encrypted gene 2)—Traces
of this transcript were found in a few control blood samples.
In contrast, some of the NTG and HTG patients demonstrated
highly increased expression levels.
Na+/Ca2+ EP1 expression values (encrypted gene 13)
—An upregulation of this transcript has been demonstrated
for glaucoma patients compared to controls.
Membrane type 1 matrix metalloproteinase (MT1-
MMP)  expression  values  (encrypted  gene  22)—A
significant  upregulation  of  this  transcript  has  been
demonstrated for glaucoma patients compared to controls.
DISCUSSION
Why is early diagnostics important for glaucoma treatment?:
Worldwide,  67  million  people  are  affected  by  the
neurodegenerative eye disease glaucoma. GON is the second
leading  cause  of  permanent  vision  loss;  it  is  a  chronic
degenerative process, the onset of which is not possible to
monitor by currently existing diagnostic tools. Early treatment
has been demonstrated to be highly beneficial for well-timed
treatment measures to slow disease progression [12].
What  is  the  potential  impact  of  predictive  molecular
diagnostics in glaucoma?: Molecular pathomechanisms of
glaucoma  demonstrate  both  a  considerable  overlap  and
remarkable particularities to some other neurodegenerative
disorders,  such  as  Alzheimer’s  and  Parkinson’s  diseases
[13].  Thus  compared  to  controls  the  NTP  demonstrates
enhanced expression levels in glaucoma, patients with Down
syndrome,  Alzheimer’s  disease,  and  some  other
neurodegenerative  diseases  indicating  axonal  lesions.
However whereas the accumulation of the TAU protein is
characteristic for Alzheimer’s disease, glaucoma patients do
not  demonstrate  an  increase  in  the  target  protein  versus
controls [12]. Therefore, monitoring of the pathology-specific
molecular  patterns  is  particularly  valuable  for  the
development  of  reliable  diagnostic  approaches  before  the
manifestation of the pathology.
What is the impact of vascular deregulation in glaucoma
pathology?: A wealth of literature points to the importance of
hemodynamics in glaucoma pathology. Vasospasm, defined
as an inappropriate constriction or insufficient dilatation in the
microcirculation, is frequently observed in glaucoma patients.
Moreover, this is also a frequent phenomenon in young female
individuals, which makes the task of glaucoma prediction and
targeted prevention particularly attractive from several points
of view.
Similarities  in  subcellular  images  detected  in  circulating
leukocytes of vasospastic individuals and glaucoma patients.:
DNA breaks have been been analyzed by the Comet Assay
technology,  and  DNA  damage  has  been  monitored  in
circulating  leukocytes  of  both  glaucoma  patients  and
vasospastic individuals compared to healthy controls. Further,
quantitative Comet Assay analysis demonstrated significantly
enhanced  levels  of  DNA  breaks  in  glaucoma  patients
compared to both healthy vasospastic and non-vasospastic
individuals and revealed pathology-specific comet patterns
[14]. From this viewpoint, vasospasm can be considered as
risk  factor  for  glaucoma,  and  Comet  Assay  imaging
technology is a promising approach to be applied for early/
predictive diagnostics.
Similarities  in  expression  patterns  detected  in  circulating
leukocytes of vasospastic individuals and glaucoma patients.:
The  following  key  pathways  are  affected  in  glaucoma
pathology:  stress  response,  apoptosis  and  DNA-repair,
adhesion, blood-brain-barrier breakdown, tissue remodeling,
transcription  regulation,  multidrug  resistance,  and  energy
metabolism [13]. Here we demonstrate significant similarities
in  expression  patterns  of  vasospastic  individuals  and
glaucoma patients as compared to healthy controls (see Figure
3).
P2Y  purinoreceptor  is  upregulated  in  vasospastic
individuals  and  glaucoma  patients—The  movement  of
leukocytes  from  blood  into  tissue  is  regulated  by  local
production  of  chemoattractants—diverse  molecules,  the
chemotactic  signal  of  which  is  transmitted  by  G-protein-
coupled purinoceptor family P2Y. These receptors respond to
chemotactic signals of traumatic, infectious, post-ischemic,
autoimmune,  and  various  toxic  injuries.  Extracellular
nucleotides released from the activated platelets and other
damaged cell types exacerbate the inflammatory response by
cell-specific  leukotrene  generation  [15].  Thus,  neutrophils
generate leukotrienes B4 (LTB4), which are involved in the
genesis of inflammation and edema because of their effect on
vascular  permeability,  plasma  extravasation,  diapedesis  of
white blood cells, and their important role in an adaptive
immune responses, as reviewed by Di Gennaro et al. [16].
Specifically, a highly enhanced concentration of leukotrienes
B4 and C4 has been observed in cerebrospinal fluid of patients
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T
Mwith  multiple  sclerosis  [17].  This  gene’s  product  is  the
member of the leukotriene receptor family (LTB4 receptor or
P2Y purinceptor 7), and for the first time, has been isolated
from the human erythroleukemia cell cDNA library [18]. One
of  the  physiological  roles  of  LTB4  is  the  stimulation  of
monocytes, neutrophils and endothelial cells [19]. There is a
growing body of evidence indicating an important role of
LTB4 receptors in the regulation of pathologic inflammation.
Particularly using animal inflammatory models, a reduced
disease  severity  has  been  shown  when  LTB4  receptor
antagonists  have  been  applied;  the  same  effect  has  been
observed  in  mice  with  target  deletion  of  BLT1—a  high-
affinity  LTB4  receptor  primarily  expressed  in  leukocytes
[20]. Furthermore, some studies support a potential role of
P2Y  receptors  in  controlling  IOP,  although  additional
investigations of this issue are necessary [21].
ICAM-1 is upregulated in vasospastic individuals and
glaucoma  patients—Neutrophil–endothelium  interactions
are  implicated  in  pathological  alterations  of  blood  vessel
function, potentially leading to circulatory disturbances [22].
Interactions between blood cells and the vessel wall result in
endothelial  dysfunction  and  injury  leading  to  increased
blood–brain barrier permeability and even edema formation
[23]. Penetration of leukocytes into inflamed areas involves a
complex interaction of leukocytes with endothelium through
regulated expression of surface adhesion molecules. Found in
this work to be highly expressed in VD, NTG, and HTG
groups, ICAM-1 is believed to be largely responsible for the
adhesion and transendothelial migration of leukocytes [24].
This is in agreement with earlier developed strategies aimed
at inhibition of endothelial interactions with leukocytes via
use  of  adhesion  molecule  monoclonal  antibodies,  which
successfully  reduce  cerebral  ischemia/reperfusion  injury,
infarct  size,  and  demonstrate  a  neuroprotective  effect
generally [25–27]. In our study, highly expressed ICAM-1
was found in leukocytes of glaucoma patients; in contrast,
only traces, if any, of the target expression was detected in the
leukocytes of healthy controls.
Sodium  calcium  exchanger—Many  studies  have
examined the levels of cytosolic Ca2+ [Ca2+]c and Na+ [Na+]c
in human blood cells. Leukocytes have been the main target
when studying the relationship between blood pressure and
intracellular content of both ions, as reviewed by Horiguchi
et al. [28]. As shown by Horiguchi et al. [28], the resting
[Ca2+]c correlates well with sodium calcium exchanger (NCE)
expression, indicating NCE expression regulation to be an
adaptive mechanism for Ca2+ extrusion mediation. Horiguchi
et  al.  also  observed  a  gender  effect  on  [Ca2+]c  /  [Na+]c
Figure 2. Comparative real-time PCR.
The measurements for the most stable
alterations (see the “Expression array”
images  as  given  in  Figure  1)  were
performed  in  glaucoma  patients
compared to controls. All measurements
have been performed by a blind study.
The names of the encrypted genes are
following:  the  gene  1=P2Y
(purinoceptor 7); the gene 2=ICAM 1
(intercellular adhesion molecule 1); the
gene  13=Na+/Ca2+  EP1  (Na+/Ca2+
exchange protein 1); the gene 22=MT1-
MMP  (membrane  type  1  matrix
metalloproteinase).
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blood pressure. Further, the role of endothelial intracellular
Ca2+  concentration  in  molecular  mechanisms  of
vasoconstriction/vasodilatation has been intensively studied,
and the functional association between P2Y purinoceptors,
endothelial nitric oxide synthesis, and calcium transport in
terms  of  vascular  regulation  is  well  documented  in  the
literature [29,30]. Our findings here clearly demonstrate the
upregulation  of  both  P2Y  purinoceptor  and  Na+/Ca2+
exchanger in circulating leukocytes of glaucoma patients as
well as vasospastic individuals versus healthy controls.
Concluding remarks: We conclude that
Figure 3. Overview of protein expression profiling. The diagram
demonstrates the overlap in molecular mechanisms among single
pathologies according to the similarities in gene expression patterns
in  vascular  deregulation  (VD),  normal-tension  (NTG)  and  high-
tension  (HTG)  glaucoma  patients  groups.  Single  disorders
demonstrate some pathology-characteristic expressions marked by
the  corresponding  symbol,  e.g.,  NTG.  Further,  there  are  partial
expression overlaps between two of three pathologies symbolized by
the corresponding pair, e.g., NTG & HTG. The similarities among
all three groups (NTG & HTG & VD) of comparison are considered
as the central issue that this study is focused on. Altogether 34 genes
that create this overlap are summarized in Table 3, providing the clue
to  the  molecular  pathomechanisms  that  potentially  predispose
vasospastic individuals to the glaucomatous pathology.
- The expressional overlap between NTG and HTG
groups versus controls (here 53 genes) indicates broad
similarities in pathomechanisms of both glaucoma forms.
- The expression similarities (altogether 34 genes)
found here between glaucoma and VD versus controls
indicate, on one hand, a predisposition of VD individuals
to  glaucomatous  damage,  and,  on  the  other  hand,  an
important  role  of  the  vascular  component  in  the
pathogenesis of glaucoma.
-  Expression  differences  (altogether  21genes)
between VD and glaucoma patients might indicate some
glaucoma-specific pathomechanisms.
-  Both  groups  of  genes  (34  and  21)  could  be
potentially useful for glaucoma diagnostics.
As  we  show  here,  this  molecular  rearrangement  in
leukocytes of both VD and glaucoma patients includes an
upregulated  adhesive  protein  expression  via  ICAM1;  an
induced chemotaxis via P2Y purinoceptors; a mobilization of
intracellular Ca2+ response via Na+/Ca2+ exchanger; and a core
of tissue-remodeling metalloproteinases.
This  molecular  rearrangement  has  been  shown  to  be
typical for circulating leukocytes during vascular injury, as
reviewed  by  Kunapoli  and  Daniel  [31].  These  pathology-
specific molecular patterns in blood may create the basis for
the  development  of  novel  noninvasive  molecular  imaging
technologies in early and predictive glaucoma diagnostics.
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